Literature DB >> 25053455

B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration.

Li-wei Zhao1, Chun Li2, Rui-lan Zhang2, Hao-gang Xue3, Fu-xi Zhang3, Fan Zhang2, Xiao-dong Gai4.   

Abstract

B7-H1 and B7-H4 are newly discovered members of the B7-CD28 family. They can inhibit T cell activation and proliferation and regulate T cell immune response negatively. Both B7-H1 and B7-H4 are expressed in many tumors and are classified as co-inhibitors of cell-mediated immunity. FOXP3(+) regulatory T cells (Tregs) play an important role in the maintenance of tumor immunity tolerance. However, the implication of B7-H1 and B7-H4 expression and their interaction with Tregs infiltration in colorectal cancer are unknown. The present study aimed to determine the expression of B7-H1 and B7-H4 as well as Tregs infiltration in colorectal cancer and to explore the clinical and pathological implication of suppressor immune cells and molecules. Frozen sections and immunohistochemical assay were undertaken to assess B7-H1, B7-H4 expression and Tregs infiltration in fresh specimens collected from 56 patients with colorectal carcinoma. The results showed that expression of B7-H1 and B7-H4 in colorectal carcinoma tissues was significantly higher than in adjacent normal mucosa (P<0.001). B7-H1 expression was positively correlated to the infiltration depth, lymph node metastasis and advanced Duke's stage (P<0.05, P<0.05 and P<0.05, respectively), whereas B7-H4 expression was positively related to the infiltration depth and lymph node metastasis (P<0.01 and P<0.05, respectively). Furthermore, Tregs infiltration was more frequent in tumor tissue than in adjacent normal mucosa and was associated with poor differentiation and positive lymph node metastasis (P<0.01, and P<0.01, respectively). The statistical analysis indicated a significant correlation between Tregs infiltration and B7-H1 or B7-H4 expression respectively. These results suggest that over-expression of B7-H1 and B7-H4 has stronger prognostic significance and promote tumor tolerance, and they might contribute to Tregs development in the colorectal carcinoma tolerogenic milieu.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  B7-H1; B7-H4; Colorectal cancer; Immunohistochemistry; Regulatory T cells

Mesh:

Substances:

Year:  2014        PMID: 25053455     DOI: 10.1016/j.acthis.2014.06.003

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  34 in total

1.  Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.

Authors:  Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Clin Exp Med       Date:  2018-01-23       Impact factor: 3.984

Review 2.  Dendritic cell-based cancer immunotherapy for colorectal cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Keisuke Saito; Shinichiro Takami; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

Review 3.  The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.

Authors:  Alexander Sankin; Deepa Narasimhulu; Peter John; Benjamin Gartrell; Mark Schoenberg; Xingxing Zang
Journal:  Urol Oncol       Date:  2017-05-08       Impact factor: 3.498

Review 4.  The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.

Authors:  Yaoan Wen; Yeda Chen; Xiaolu Duan; Wei Zhu; Chao Cai; Tuo Deng; Guohua Zeng
Journal:  Clin Exp Med       Date:  2019-08-12       Impact factor: 3.984

Review 5.  Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.

Authors:  Feng Xu; Lingling Xu; Qian Wang; Guangyu An; Guosheng Feng; Fuquan Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 6.  Potential targeting of B7-H4 for the treatment of cancer.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 7.  The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.

Authors:  Murali Janakiram; Urvi A Shah; Weifeng Liu; Aimin Zhao; Mark P Schoenberg; Xingxing Zang
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Juhong Yang; Kosuke Mima; Annacarolina da Silva; Yan Shi; Kentaro Inamura; Yin Cao; Mingyang Song; Jonathan A Nowak; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott Rodig; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Gut       Date:  2016-05-05       Impact factor: 23.059

9.  Fibrosis and Mast Cells in Colorectal Lesions: Significance in Adenoma-Colorectal Cancer Sequence and Association with Diet.

Authors:  Izabela Sinara Silva Alves; Pedro Henrique Piras Coser; Giovanni José Zucoloto Loureiro; Luciano Pinto Nogueira da Gama; Flavya da Silva Souza Ribeiro; Willian Grassi Bautz; Karla Loureiro Almeida Coburn; Marcos da Silva Pacheco; Letícia Nogueira da Gama de Souza
Journal:  J Gastrointest Cancer       Date:  2016-09

10.  B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.

Authors:  Zhao Lu; Zhi-Xun Zhao; Pu Cheng; Fei Huang; Xu Guan; Ming-Guang Zhang; Hai-Peng Chen; Zheng Liu; Zheng Jiang; Zhao-Xu Zheng; Shuang-Mei Zou; Xi-Shan Wang
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.